Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SCScribe Therapeutics Inc. logo

Scribe Therapeutics Inc. (SCTX)

NASDAQ · Currency in USD
$15.41 ▼ -2.56 (-14.23%)
At close: Oct 23, 4:00 PM ET. Market closed.
$15.75 ▲ +0.35 (+2.24%)
After hours: Oct 23, 7:57 PM ET

Summary

Previous Close
$17.96
Open
$18.55
Day's Range
$15.12 – $18.55
52 Week Range
$13.50 – $39.60
Volume
861,395
Avg. Volume
375,259
Market Cap
$249.28M
Beta (5Y Monthly)
0.00
PE Ratio (TTM)
--
EPS (TTM)
--
Earnings Date
Dec 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$51.75

Profile: Scribe Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
82
CEO
Benjamin L. Oakes

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Earnings

Next report: Wed, Dec 2, 2026
EPS estimate -$0.42 · Revenue est. $3.72M
DateEst.Actual
Sep 2, 2026-$3.62-$2.62Beat

Analyst view

Consensus price target
$51.75 ▲ +235.9%
Range $37.00 – $60.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on SCTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.